ProCE Banner Activity

Hepatitis C Management in Special Populations

Text Module

In this module, CCO’s expert faculty review the latest data and available treatment guidelines on the optimal management of hepatitis C in special populations, including persons who inject drugs, patients with renal disease, patients with HIV coinfection, children, pregnant women, and liver transplant recipients.

Released: December 28, 2020

Expiration: December 27, 2021

Share

Faculty

Mark S. Sulkowski

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Stefan Zeuzem

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from:

AbbVie

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from AbbVie, Gilead Sciences, and Merck.

Faculty Disclosure

Primary Author

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received consulting fees from AbbVie, Achillion, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck, and has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, as no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, as no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.